News
Hospital trust launches Badger Notes maternity app
The app is hoped to replace the traditional, paper-based blue maternity notes folder
A new pregnancy app has launched in Oxfordshire, giving women instant access to their maternity records.
Bosses at Oxford University Hospitals NHS Foundation Trust (OUH) said Badger Notes, available to download via Apple App Store or Google Play Store, would replace paper notes, giving patients “real-time access” to their maternity care record.
Women being cared for by the trust’s maternity services, they said, would be able to access their records and other information related to their pregnancy more effectively from a phone, tablet or computer.
Expectant mothers would be able to add preferences, such as where they want to give birth and details of their birthing partner. Midwives would also be able to share relevant resources directly via the app.
Badger Notes, used widely in maternity units across the UK, was launched at OUH in two phases, for antenatal care in January and for intrapartum and postnatal care in February.
The project has been implemented by clinical and digital teams and staff across the trust completed their training on the system in recent months.
Jennifer Mearns, a digital midwife at OUH, said: “Digital notes are used widely across the NHS and help clinicians access information and provide a better – and safer – care experience for women in our community.
“Our aim is to increase choice and personalisation for women during their pregnancy journey, empowering them to take greater ownership of their maternity care by using Badger Notes, a more secure way of storing information than carrying the bulky paper file.
“BadgerNet, the portal for clinical staff, also makes it easier for healthcare professionals to share medical information and maternity records in one place if needed. We are thrilled to launch this transformative project.”
BadgerNet stores all medical notes so if a service user attends another NHS trust unexpectedly, any doctor or midwife using BadgerNet in the UK can access their care and history quickly.
David Walliker, chief digital and partnership officer at OUH, said: “In our trust strategy, launched in 2020, we set ‘digital by default’ as a key strategic theme as we aim to deliver on our vision to deliver digitally enabled care.
“The launch of the BadgerNet portal and Badger Notes app at OUH provides an electronic patient record (EPR) for women being cared for by our maternity teams.”
Paula Gardner, interim chief nursing officer at OUH, added: “This is an exciting development for our families and our maternity staff, and I am thankful to all the staff who made it possible, as we strive to deliver compassionate excellence.”
Bosses assured patients the medical notes would remain confidential and would only be seen by the service user and healthcare professionals involved in the woman’s care.
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment